Study to Assess Adverse Events and Pharmacokinetics in Adult Participants With Non-Small Cell Lung Cancer (NSCLC), Head and Neck Squamous Cell Carcinoma (HNSCC) and Other Solid Tumors, Receiving Intravenous (IV) Infusion of Azirkitug (ABBV-514) Alone or in Combination With Budigalimab or Bevacizumab

Inclusion Criteria:

• Pre Treatment biopsy or archive tissue within 6 months without intervening treatment

• Eastern Cooperative Oncology Group (ECOG) performance status of <=1

• Measurable disease per Response Evaluation Criteria in Solid Tumors (RECIST)

• Laboratory values meeting criteria outlined in the protocol

• NSCLC - Advanced or metastatic progressed on standard of care (SOC) includingchemotherapy and prior anti-PD-(L)1 antibody (separately or in combination).Actionable gene alterations are eligible if failed targeted therapeutic options.

• HSNCC - Advanced/metastatic progressed on platinum and PD-1/PD-LI in recurrent ormetastatic setting.

• Micro Satellite Stable Colorectal Cancer (MSS-CRC) - Progressed on Oxaliplatin,Irinotecan, a fluoropyrimidine, anti-EGFR, VEGF or VEGFR therapies, TAS-102,Regorafenib and not MSI-h or MMR-deficient

• Gastric and Gastroesophageal Junction adenocarcinoma (GEA) - Advanced/metastaticprogressed on at least 1 prior cytotoxic chemotherapeutic regimen and if applicableimmune checkpoint inhibitor and/or HER2 therapy

• High-Grade Serous Ovarian Cancer (HGSOC) - Progressed serous epithelial ovarian,fallopian tube or primary peritoneal cancer post SOC and not eligible for surgicalresection. Platinum resistant cannot have >5 lines of prior therapy.

• Pancreatic Adenocarcinoma (PDAC) - Advanced/metastatic progressed after SOC.Includes adenosquamous carcinoma and post-Whipple.

• Triple Negative Breast Cancer (TNBC) - Progressed after >1 systemic therapy thatmust have included taxane and treatment naïve to immunotherapy targeting T-cellco-stimulation

Exclusion Criteria:

• Pancreatic Ductal Adenocarcinoma (PDAC) - Excludes neuroendocrine or acinarpancreatic carcinoma and participants with coagulopathy or at risk of or history ofDeep vein thrombosis (DVT)/PE

• No major surgery within 28 days prior to dosing

• No active autoimmune/immunodeficiency disease with limited exceptions

• Combination treatment excludes participants treated with anti-programmed cell deathprotein 1(PD-1)/Programmed cell death ligand 1 (PD-L1) who had immune mediatedtoxicity G3 or greater, interstitial lung disease, or hypersensitivity Combinationtreatment may also require no significant cardiac deficiencies and/or events

• Pregnancy

• Excluded medications include anticancer therapy within 5 half-live or 28 days (whichever is shorter), agent targeting Chemokine Receptor (CCR)8, live vaccines,immunosuppressive medication with limited exceptions